Symptomatic ventricular tachyarrhythmia is associated with delayed gadolinium enhancement in cardiac magnetic resonance imaging and with elevated plasma brain natriuretic peptide level in hypertrophic cardiomyopathy

Journal of Cardiology

Volumn 52, Issue 2, 2008, Pages 146-153

  Oka, Katsumi ^a   Tsujino, Takeshi ^a   Nakao, Shinji ^a   Lee Kawabata, Masaaki ^a   Ezumi, Akira ^a   Masai, Miho ^a   Ohyanagi, Mitsumasa ^a   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Brain natriuretic peptide; Cardiac magnetic resonance imaging; Delayed gadolinium enhancement; Hypertrophic cardiomyopathy; Ventricular tachycardia

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GADOLINIUM;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEOMETRY; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LOGISTIC REGRESSION ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIODIAGNOSIS; SYMPTOMATOLOGY;

AGED; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 52049091873     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.07.003     Document Type: Article

References (33)

1. McKenna W.J., and Behr E.R. Hypertrophic cardiomyopathy: management, risk stratification, and prevention of sudden death. Heart 87 (2002) 169-176
2. Maron B.J., Shen W.K., Link M.S., Epstein A.E., Almquist A.K., Daubert J.P., et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 342 (2000) 365-373
3. Elliott P.M., Poloniecki J., Dickie S., Sharma S., Monserrat L., Varnava A., et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 36 (2000) 2212-2218
4. Cecchi F., Olivotto I., Gistri R., Lorenzoni R., Chiriatti G., and Camici P.G. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349 (2003) 1027-1035
5. Kim R.J., and Judd R.M. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death?. J Am Coll Cardiol 41 (2003) 1568-1572
6. Moon J.C., McKenna W.J., McCrohon J.A., Elliott P.M., Smith G.C., and Pennell D.J. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 41 (2003) 1561-1567
7. Kwon D.H., Setser R.M., Popović Z.B., Thamilarasan M., Sola S., Schoenhagen P., et al. Association of myocardial fibrosis, electrocardiography and ventricular tachyarrhythmia in hypertrophic cardiomyopathy: a delayed contrast enhanced MRI study. Int J Cardiovasc Imaging January (2008) [Epub ahead of print]
8. Adabag A.S., Maron B.J., Appelbaum E., Harrigan C.J., Buros J.L., Gibson C.M., et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51 (2008) 1369-1374
9. Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88 (1993) 372-380
10. Maron B.J., Tholakanahalli V.N., Zenovich A.G., Casey S.A., Duprez D., Aeppli D.M., et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109 (2004) 984-989
11. Thaman R., Esteban M.T., Barnes S., Gimeno J.R., Mist B., Murphy R., et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 515-519
12. Binder J., Ommen S.R., Chen H.H., Ackerman M.J., Tajik A.J., and Jaffe A.S. Usefulness of brain natriuretic peptide levels in the clinical evaluation of patients with hypertrophic cardiomyopathy. Am J Cardiol 100 (2007) 712-714
13. Nishigaki K., Tomita M., Kagawa K., Noda T., Minatoguchi S., Oda H., et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 28 (1996) 1234-1242
14. Okawa M., Kitaoka H., Matsumura Y., Kubo T., Yamasaki N., Furuno T., et al. Functional assessment by myocardial performance index (Tei index) correlates with plasma brain natriuretic peptide concentration in patients with hypertrophic cardiomyopathy. Circ J 69 (2005) 951-957
15. Briguori C., Betocchi S., Manganelli F., Gigante B., Losi M.A., Ciampi Q., et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J 22 (2001) 1328-1336
16. Nakamura T., Sakamoto K., Yamano T., Kikkawa M., Zen K., Hikosaka T., et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 39 (2002) 1657-1663
17. Mutlu B., Bayrak F., Kahveci G., Degertekin M., Eroglu E., and Basaran Y. Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy. Am J Cardiol 98 (2006) 1504-1506
18. Klues H.G., Schiffers A., and Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimentional echocardiography in 600 patients. J Am Coll Cardiol 26 (1995) 1699-1708
19. Report of the 1995 World Health Organization/Intenational Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation 1996; 93:841-842.
20. Maron M.S., Olivotto I., Betocchi S., Casey S.A., Lesser J.R., Losi M.A., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
21. Cerqueira M.D., Weissman N.J., Dilsizian V., Jacobs A.K., Kaul S., Laskey W.K., et al., American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
22. Dimitrow P.P., Klimeczek P., Vliegenthart R., Pasowicz M., Oudkerk M., Podolec P., et al. Late hyperenhancement in gadolinium-enhanced magnetic resonance imaging: comparison of hypertrophic cardiomyopathy patients with and without nonsustained ventricular tachycardia. Int J Cardiovasc Imaging 24 (2008) 77-83
23. Weinmann H.J., Brasch R.C., Press W.R., and Wesbey G.E. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 142 (1984) 619-624
24. Polimeni P.I. Extracellular space and ionic distribution in rat ventricle. Am J Physiol 227 (1974) 676-683
25. Moon J.C., Reed E., Sheppard M.N., Elkington A.G., Ho S.Y., Burke M., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43 (2004) 2260-2264
26. Maron B.J., and Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol 81 (1998) 1339-1344
27. Maron B.J., Wolfson J.K., Epstein S.E., and Roberts W.C. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8 (1986) 545-557
28. Krams R., Kofflard M.J., Duncker D.J., Von Birgelen C., Carlier S., Kliffen M., et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 97 (1998) 230-233
29. Lazzeroni E., Picano E., Morozzi L., Maurizio A.R., Palma G., Ceriati R., et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Echo Persantine Italian Cooperative (EPIC) Study Group, Subproject Hypertrophic Cardiomyopathy. Circulation 96 (1997) 4268-4272
30. Takemura G., Takatsu Y., and Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart 79 (1998) 78-85
31. Kyriakidis M., Triposkiadis F., Dernellis J., Androulakis A.E., Mellas P., Kelepeshis G.A., et al. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 97 (1998) 1342-1347
32. Kaski J.P., Tome-Esteban M.T., Mead-Regan S.J., Pantazis A., Marek J., Deanfield J.E., et al. B-type natriuretic peptide predicts disease severity in children with hypertrophic cardiomyopathy. Heart December (2007) [Epub ahead of print]
33. Weidemann A., Klanke B., Wagner M., Volk T., Willam C., Wiesener M.S., et al. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J 409 (2008) 233-242